Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuzo Ohno

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|March 5, 2003
Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCRKazuoki Osumi, Takafumi Fukui, Hitoshi Kiyoi, et al.
European Journal of Haematology|July 11, 2006
Clinicopathological and prognostic characteristics of CD33-positive multiple myelomaNaohi Sahara, Kazunori Ohnishi, Takaaki Ono, et al.
Blood|August 19, 2004
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemiaMasayuki Towatari, Masamitsu Yanada, Noriko Usui, et al.
Leukemia & Lymphoma|August 5, 2004
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathwayNaohi Sahara, Akihiro Takeshita, Miki Kobayashi, et al.
International Journal of Hematology|January 12, 2010
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 studyHisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, et al.
Japanese Journal of Cancer Research : Gann|April 30, 2003
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysisYasuyuki Kaneta, Yoshitoyo Kagami, Toyomasa Katagiri, et al.
International Journal of Hematology|March 15, 2006
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agentAkihiro Takeshita, Kaori Shinjo, Kensuke Naito, et al.
British Journal of Haematology|April 25, 2009
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphomaAkihiro Takeshita, Kaori Shinjo, Nozomi Yamakage, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2006
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxideShinya Fujisawa, Ryuzo Ohno, Kazuyuki Shigeno, et al.
Cancer|November 15, 2005
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 StudyShuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|March 5, 2003
Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCRKazuoki Osumi, Takafumi Fukui, Hitoshi Kiyoi, et al.
European Journal of Haematology|July 11, 2006
Clinicopathological and prognostic characteristics of CD33-positive multiple myelomaNaohi Sahara, Kazunori Ohnishi, Takaaki Ono, et al.
Blood|August 19, 2004
Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemiaMasayuki Towatari, Masamitsu Yanada, Noriko Usui, et al.
Leukemia & Lymphoma|August 5, 2004
Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathwayNaohi Sahara, Akihiro Takeshita, Miki Kobayashi, et al.
International Journal of Hematology|January 12, 2010
Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 studyHisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, et al.
Japanese Journal of Cancer Research : Gann|April 30, 2003
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysisYasuyuki Kaneta, Yoshitoyo Kagami, Toyomasa Katagiri, et al.
International Journal of Hematology|March 15, 2006
Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agentAkihiro Takeshita, Kaori Shinjo, Kensuke Naito, et al.
British Journal of Haematology|April 25, 2009
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphomaAkihiro Takeshita, Kaori Shinjo, Nozomi Yamakage, et al.
Cancer Chemotherapy and Pharmacology|August 29, 2006
Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxideShinya Fujisawa, Ryuzo Ohno, Kazuyuki Shigeno, et al.
Cancer|November 15, 2005
A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 StudyShuichi Miyawaki, Hisashi Sakamaki, Shigeki Ohtake, et al.
Pageof 8